universal bcma car-t
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2024 (NCT06485232)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- BCMAImmunity, passive
BCMA immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06999031 | Early Phase 1 (Phase 1) | Sep 5, 2024 | Nanchang University |
| NCT06485232 | Early Phase 1 (Phase 1) | Aug 1, 2024 | Capital Medical University, Shanghai Bioray Laboratory Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Nanchang University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Shanghai Bioray Laboratory Inc. | For profit | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1